ObsEva (NASDAQ:OBSV) Earns Hold Rating from Analysts at StockNews.com

Posted by on Apr 11th, 2025

StockNews.com started coverage on shares of ObsEva (NASDAQ:OBSV – Free Report) in a research report released on Tuesday. The firm issued a hold rating on the stock.

ObsEva Stock Down 100.0 %

The firm has a market cap of $7.94 million, a P/E ratio of -0.11 and a beta of 0.68. ObsEva has a one year low of $0.08 and a one year high of $2.14.

ObsEva Company Profile

(Get Free Report)

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Read More

Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.